Estrogen deficiency and bone loss: An inflammatory tale

Journal of Clinical Investigation

Volumn 116, Issue 5, 2006, Pages 1186-1194

  Weitzmann, M Neale ^a   Pacifici, Roberto ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; TUMOR NECROSIS FACTOR;

BONE DESTRUCTION; BONE STRUCTURE; BONE TURNOVER; DISEASE ASSOCIATION; ESTROGEN DEFICIENCY; ESTROGEN RELEASE; HUMAN; INFLAMMATION; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; THYMUS;

ANIMALS; ESTROGENS; FEMALE; HUMANS; INFLAMMATION; MICE; MODELS, BIOLOGICAL; OSTEOPOROSIS; REACTIVE OXYGEN SPECIES;

EID: 33646396235     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI28550     Document Type: Review

References (123)

1. Bouxsein, M.L., et al. 2005. Ovariectomy-induced bone loss varies among inbred strains of mice. J. Bone Miner. Res. 20:1085-1092.
2. Komm, B.S., et al. 1988. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science. 241:81-84.
3. Tomkinson, A., Gevers, E.F., Wit, J.M., Reeve, J., and Noble, B.S. 1998. The role of estrogen in the control of rat osteocyte apoptosis. J. Bone Miner. Res. 13:1243-1250.
4. Oursler, M.J., Osdoby, P., Pyfferoen, J., Riggs, B.L., and Spelsberg, T.C. 1991. Avian osteoclasts as estrogen target cells. Proc. Natl. Acad. Sci. U. S. A. 88:6613-6617.
5. Weitzmann, M.N., and Pacifici, R. 2005. The role of T lymphocytes in bone metabolism. Immunol. Rev. 208:154-168.
6. Kuiper, G.G., Enmark, E., Pelto-Huikko, M., Nilsson, S., and Gustafsson, J.A. 1996. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U. S. A. 93:5925-5930.
7. Barkhem, T., et al. 1998. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol. Pharmacol. 54:105-112.
8. Hall, J.M., and McDonnell, D.P. 1999. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology. 140:5566-5578.
9. Kousteni, S., et al. 2001. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 104:719-730.
10. Sims, N.A., et al. 2003. A functional androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradiol receptor-deficient mice. J. Clin. Invest. 111:1319-1327. doi:10.1172/ JCI200317246.
11. Smith, C.L., and O'Malley, B.W. 2004. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25:45-71.
12. Stein, B., and Yang, M.X. 1995. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol. Cell. Biol. 15:4971-4979.
13. Srivastava, S., et al. 1998. Estrogen blocks M-CSF gene expression and osteoclast formation by regulating phosphorylation of Egr-1 and its interaction with Sp-1. J. Clin. Invest. 102:1850-1859.
14. Srivastava, S., et al. 1999. Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-jun and junD. J. Clin. Invest. 104:503-513.
15. Srivastava, S., et al. 2001. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J. Biol. Chem. 276:8836-8840.
16. Kousteni, S., et al. 2003. Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J. Clin. Invest. 111:1651-1664. doi:10.1172/JCI200317261.
17. Frost, H.M. 1983. Bone histomorphometry: analysis of trabecular bone dynamics. In Bone histomorphometry: techniques and interpretation. R.R. Recker, editor. CRC Press. Boca Raton, Florida, USA. 109-131.
18. Riggs, B.L., Khosla, S., and Melton, L.J., 3rd. 2002. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23:279-302.
19. Eriksen, E.F., Langdahl, B., Vesterby, A., Rungby, J., and Kassem, M. 1999. Hormone replacement therapy prevents osteoclastic hyperactivity: a histomorphometric study in early postmenopausal women. J. Bone Miner. Res. 14:1217-1221.
20. Hughes, D.E., et al. 1996. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat. Med. 2:1132-1136.
21. Jilka, R.L., et al. 1998. Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. J. Clin. Invest. 101:1942-1950.
22. Weitzmann, M.N., Roggia, C., Toraldo, G., Weitzmann, L., and Pacifici, R. 2002. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J. Clin. Invest. 110:1643-1650. doi:10.1172/JCI200317261.
23. Gilbert, L., et al. 2000. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology. 141:3956-3964.
24. Eriksen, E.F., et al. 1990. Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J. Bone Miner. Res. 5:311-319.
25. Riggs, B.L., and Parfitt, A.M. 2005. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J. Bone Miner. Res. 20:177-184.
26. Vedi, S., et al. 1999. Bone remodeling and structure in postmenopausal women treated with long-term, high-dose estrogen therapy. Osteoporos. Int. 10:52-58.
27. Manolagas, S.C. 2000. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21:115-137.
28. Manolagas, S.C., Kousteni, S., and Jilka, R.L. 2002. Sex steroids and bone. Recent Prog. Horm. Res. 57:385-409.
29. Teitelbaum, S.L. 2000. Bone resorption by osteoclasts. Science. 289:1504-1508.
30. Khosla, S. 2001. Minireview: the OPG/RANKL/RANK system. Endocrinology. 142:5050-5055.
31. Kim, N., et al. 2005. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J. Exp. Med. 202:589-595.
32. Hofbauer, L.C., et al. 1999. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone. 25:255-259.
33. Cenci, S., et al. 2000. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α. J. Clin. Invest. 106:1229-1237.
34. Lam, J., et al. 2000. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106:1481-1488.
35. Zhang, Y.H., Heulsmann, A., Tondravi, M.M., Mukherjee, A., and Abu-Amer, Y. 2001. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J. Biol. Chem. 276:563-568.
36. Fuller, K., Murphy, C., Kirstein, B., Fox, S.W., and Chambers, T.J. 2002. TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology. 143:1108-1118.
37. Nanes, M.S. 2003. Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene. 321:1-15.
38. Wei, S., Kitaura, H., Zhou, P., Ross, F.P., and Teitelbaum, S.L. 2005. IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Invest. 115:282-290. doi:10.1172/JCI200317261.
39. Pfeilschifter, J., Koditz, R., Pfohl, M., and Schatz, H. 2002. Changes in proinflammatory cytokine activity after menopause. Endocr. Rev. 23:90-119.
40. Roggia, C., et al. 2001. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl. Acad. Sci. U. S. A. 98:13960-13965.
41. Ammann, P., et al. 1997. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J. Clin. Invest. 99:1699-1703.
42. Kimble, R., Bain, S., and Pacifici, R. 1997. The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice. J. Bone Min. Res. 12:935-941.
43. Pacifici, R., et al. 1991. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc. Natl. Acad. Sci. U. S. A. 88:5134-5138.
44. Ralston, S.H., Russell, R.G.G., and Gowen, M. 1990. Estrogen inhibits release of tumor necrosis factor from peripheral blood mononuclear cells in postmenopausal women. J. Bone Miner. Res. 5:983-988.
45. Shanker, G., Sorci-Thomas, M., and Adams, M.R. 1994. Estrogen modulates the expression of tumor necrosis factor alpha mRNA in phorbol ester-stimulated human monocytic THP-1 cells. Lymphokine Cytokine Res. 13:377-382.
46. Abrahamsen, B., Bendtzen, K., and Beck-Nielsen, H. 1997. Cytokines and T-lymphocyte subsets in healthy post-menopausal women: estrogen retards bone loss without affecting the release of IL-1 or IL-1ra. Bone. 20:251-258.
47. Grcevic, D., Lee, S.K., Marusic, A., and Lorenzo, J.A. 2000. Depletion of CD4 and CD8 T lymphocytes in mice in vivo enhances 1, 25- dihydroxyvitamin D(3)-stimulated osteoclast-like cell formation in vitro by a mechanism that is dependent on prostaglandin synthesis. J. Immunol. 165:4231-4238.
48. Kong, Y.Y., et al. 1999. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 402:304-309.
49. Horwood, N.J., et al. 1999. Activated T lymphocytes support osteoclast formation in vitro. Biochem. Biophys. Res. Commun. 265:144-150.
50. Weitzmann, M.N., et al. 2001. T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. J. Bone Miner. Res. 16:328-337.
51. Takayanagi, H., et al. 2000. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature. 408:600-605.
52. Gao, Y., et al. 2004. Estrogen prevents bone loss through transforming growth factor beta signaling in T cells. Proc. Natl. Acad. Sci. U. S. A. 101:16618-16623.
53. Cenci, S., et al. 2003. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc. Natl. Acad. Sci. U. S. A. 100:10405-10410.
54. Grassi, F., and Pacifici, R. 2005. Ovariectomy increases the formation of T cell niches at the resorption surfaces. J. Bone Miner. Res. 20:Abs F395.
55. Adamski, J., Ma, Z., Nozell, S., and Benveniste, E.N. 2004. 17beta-Estradiol inhibits class II major histocompatibility complex (MHC) expression: influence on histone modifications and cbp recruitment to the class II MHC promoter. Mol. Endocrinol. 18:1963-1974.
56. Robey, E.A., et al. 1992. A self-reactive T cell population that is not subject to negative selection. Int. Immunol. 4:969-974.
57. Rammensee, H.G., Falk, K., and Rotzschke, O. 1993. Peptides naturally presented by MHC class I molecules. Annu. Rev. Immunol. 11:213-244.
58. Grossman, Z., and Paul, W.E. 2000. Self-tolerance: context dependent tuning of T cell antigen recognition. Semin. Immunol. 12:197-203; discussion 257-344.
59. Tanchot, C., Lemonnier, F.A., Perarnau, B., Freitas, A.A., and Rocha, B. 1997. Differential requirements for survival and proliferation of CD8 naive or memory T cells. Science. 276:2057-2062.
60. Boss, J.M., and Jensen, P.E. 2003. Transcriptional regulation of the MHC class II antigen presentation pathway. Curr. Opin. Immunol. 15:105-111.
61. Baker, P.J., et al. 1999. CD4(+) T cells and the proinflammatory cytokines gamma interferon and interleukin-6 contribute to alveolar bone loss in mice. Infect. Immun. 67:2804-2809.
62. Arnoldi, J., Gerdes, J., and Flad, H.D. 1990. Immunohistologic assessment of cytokine production of infiltrating cells in various forms of leprosy. Am. J. Pathol. 137:749-753.
63. Firestein, G.S., Alvaro-Gracia, J.M., and Maki, R.. 1990. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J. Immunol. 144:3347-3353.
64. Key, L.L., Jr., et al. 1995. Long-term treatment of osteopetrosis with recombinant human interferon gamma. N. Engl. J. Med. 332:1594-1599.
65. Rodriguiz, R.M., Key, L.L., Jr., and Ries, W.L. 1993. Combination macrophage-colony stimulating factor and interferon-gamma administration ameliorates the osteopetrotic condition in microphthalmic (mi/mi) mice. Pediatr. Res. 33:384-389.
66. Vermeire, K., et al. 1997. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J. Immunol. 158:5507-5513.
67. Sato, K., et al. 1992. Prolonged decrease of serum calcium concentration by murine gamma-interferon in hypercalcemic, human tumor (EC-GI)-bearing nude mice. Cancer Res. 52:444-449.
68. Tohkin, M., Kakudo, S., Kasai, H., and Arita, H. 1994. Comparative study of inhibitory effects by murine interferon gamma and a new bisphosphonate (alendronate) in hypercalcemic, nude mice bearing human tumor (LJC-1-JCK). Cancer Immunol. Immunother. 39:155-160.
69. Kotake, S., et al. 2005. IFN-gamma-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL. Eur. J. Immunol. 35:3353-3363.
70. Huang, W., O'Keefe, R.J., and Schwarz, E.M. 2003. Exposure to receptor-activator of NFkappaB ligand renders pre-osteoclasts resistant to IFN-gamma by inducing terminal differentiation. Arthritis. Res. Ther. 5:R49-R59.
71. Yang, N.N., Venugopalan, M., Hardikar, S., and Glasebrook, A. 1996. Identification of an estrogen response element activated by metabolites of 17b-estradiol and raloxifene. Science. 273:1222-1225.
72. Miyaura, C., et al. 1997. Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function: similarity to estrogen deficiency. Proc. Natl. Acad. Sci. U. S. A. 19:9360-9365.
73. Valenzona, H.O., Pointer, R., Ceredig, R., and Osmond, D.G. 1996. Prelymphomatous B cell hyperplasia in the bone marrow of interleukin-7 transgenic mice: precursor B cell dynamics, microenvironmental organization and osteolysis. Exp. Hematol. 24:1521-1529.
74. Weitzmann, M.N., Cenci, S., Rifas, L., Brown, C., and Pacifici, R. 2000. Interleukin-7 stimulates osteoclast formation by up-regulating the T- cell production of soluble osteoclastogenic cytokines. Blood. 96:1873-1878.
75. Toraldo, G., Roggia, C., Qian, W.P., Pacifici, R., and Weitzmann, M.N. 2003. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc. Natl. Acad. Sci. U. S. A. 100:125-130.
76. Ryan, M.R., et al. 2005. An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency. Proc. Natl. Acad. Sci. U. S. A. 102:16735-16740.
77. Lindberg, M.K., et al. 2006. Liver-derived IGF-I is permissive for ovariectomy-induced trabecular bone loss. Bone. 38:85-92.
78. Lee, S.K., et al. 2006. Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss. J. Bone Miner. Res. doi:10.1359/jbmr.060117.
79. Huang, M., et al. 2002. IL-7 inhibits fibroblast TGF-β production and signaling in pulmonary fibrosis. J. Clin. Invest. 109:931-937. doi:10.1172/JCI200214685.
80. Dubinett, S.M., et al. 1995. Down-regulation of murine fibrosarcoma transforming growth factor-beta 1 expression by interleukin 7. J. Natl. Cancer Inst. 87:593-597.
81. Giuliani, N., et al. 2002. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood. 100:4615-4621.
82. van Roon, J.A., Glaudemans, K.A., Bijlsma, J.W., and Lafeber, F.P. 2003. Interleukin 7 stimulates tumour necrosis factor alpha and Th1 cytokine production in joints of patients with rheumatoid arthritis. Ann. Rheum. Dis. 62:113-119.
83. De Benedetti, F., et al. 1995. Elevated circulating interleukin-7 levels in patients with systemic juvenile rheumatoid arthritis. J. Rheumatol. 22:1581-1585.
84. Masuzawa, T., et al. 1994. Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow. J. Clin. Invest. 94:1090-1097.
85. Manabe, N., et al. 2001. Connection between B lymphocyte and osteoclast differentiation pathways. J. Immunol. 167:2625-2631.
86. Sato, T., Shibata, T., Ikeda, K., and Watanabe, K. 2001. Generation of bone-resorbing osteoclasts from B220+ cells: its role in accelerated osteoclastogenesis due to estrogen deficiency. J. Bone Miner. Res. 16:2215-2221.
87. Haynes, B.F., Sempowski, G.D., Wells, A.F., and Hale, L.P. 2000. The human thymus during aging. Immunol. Res. 22:253-261.
88. Douek, D.C., and Koup, R.A. 2000. Evidence for thymic function in the elderly. Vaccine. 18:1638-1641.
89. Jamieson, B.D., et al. 1999. Generation of functional thymocytes in the human adult. Immunity. 10:569-575.
90. Steinmann, G.G., Klaus, B., and Muller-Hermelink, H.K. 1985. The involution of the ageing human thymic epithelium is independent of puberty. A morphometric study. Scand. J. Immunol. 22:563-575.
91. Hakim, F.T., et al. 2005. Age-dependent incidence, time course, and consequences of thymic renewal in adults. J. Clin. Invest. 115:930-939. doi:10.1172/JCI200317261.
92. Mackall, C.L., et al. 2001. IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation. Blood. 97:1491-1497.
93. Chu, Y.W., et al. 2004. Exogenous IL-7 increases recent thymic emigrants in peripheral lymphoid tissue without enhanced thymic function. Blood. 104:1110-1119.
94. Alpdogan, O., et al. 2001. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood. 98:2256-2265.
95. Utsuyama, M., and Hirokawa, K. 1989. Hypertrophy of the thymus and restoration of immune functions in mice and rats by gonadectomy. Mech. Ageing Dev. 47:175-185.
96. Okasha, S.A., et al. 2001. Evidence for estradiol-induced apoptosis and dysregulated T cell maturation in the thymus. Toxicology. 163:49-62.
97. Roden, A.C., et al. 2004. Augmentation of T cell levels and responses induced by androgen deprivation. J. Immunol. 173:6098-6108.
98. Sutherland, J.S., et al. 2005. Activation of thymic regeneration in mice and humans following androgen blockade. J. Immunol. 175:2741-2753.
99. Hreshchyshyn, M.M., Hopkins, A., Zylstra, S., and Anbar, M. 1988. Effects of natural menopause, hysterectomy, and oophorectomy on lumbar spine and femoral neck bone densities. Obstet. Gynecol. 72:631-638.
100. Basu, S., Michaelsson, K., Olofsson, H., Johansson, S., and Melhus, H. 2001. Association between oxidative stress and bone mineral density. Biochem. Biophys. Res. Commun. 288:275-279.
101. Maggio, D., et al. 2003. Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. J. Clin. Endocrinol. Metab. 88:1523-1527.
102. Muthusami, S., et al. 2005. Ovariectomy induces oxidative stress and impairs bone antioxidant system in adult rats. Clin. Chim. Acta. 360:81-86.
103. Lean, J.M., et al. 2003. A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J. Clin. Invest. 112:915-923. doi:10.1172/JCI200317261.
104. Wimalawansa, S.J., De Marco, G., Gangula, P., and Yallampalli, C. 1996. Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone. 18:301-304.
105. Hao, Y.J., Tang, Y., Chen, F.B., and Pei, F.X. 2005. Different doses of nitric oxide donor prevent osteoporosis in ovariectomized rats. Clin. Orthop. Relat. Res. 435:226-231.
106. Jamal, S.A., Cummings, S.R., and Hawker, G.A. 2004. Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial. J. Bone Miner. Res. 19:1512-1517.
107. Steinbeck, M.J., Appel, W.H., Jr., Verhoeven, A.J., and Karnovsky, M.J. 1994. NADPH-oxidase expression and in situ production of superoxide by osteoclasts actively resorbing bone. J. Cell Biol. 126:765-772.
108. Ha, H., et al. 2004. Reactive oxygen species mediate RANK signaling in osteoclasts. Exp. Cell Res. 301:119-127.
109. Lean, J.M., Jagger, C.J., Kirstein, B., Fuller, K., and Chambers, T.J. 2005. Hydrogen peroxide is essential for estrogen-deficiency bone loss and osteoclast formation. Endocrinology. 146:728-735.
110. Reth, M. 2002. Hydrogen peroxide as second messenger in lymphocyte activation. Nat. Immunol. 3:1129-1134.
111. Lean, J., Kirstein, B., Urry, Z., Chambers, T., and Fuller, K. 2004. Thioredoxin-1 mediates osteoclast stimulation by reactive oxygen species. Biochem. Biophys. Res. Commun. 321:845-850.
112. Chen, J.R., et al. 2005. Transient versus sustained phosphorylation and nuclear accumulation of ERKs underlie anti-versus pro-apoptotic effects of estrogens. J. Biol. Chem. 280:4632-4638.
113. Jagger, C.J., Lean, J.M., Davies, J.T., and Chambers, T.J. 2005. Tumor necrosis factor-alpha mediates osteopenia caused by depletion of antioxidants. Endocrinology. 146:113-118.
114. Mizuashi, M., Ohtani, T., Nakagawa, S., and Aiba, S. 2005. Redox imbalance induced by contact sensitizers triggers the maturation of dendritic cells. J. Invest. Dermatol. 124:579-586.
115. Rutault, K., Alderman, C., Chain, B.M., and Katz, D.R. 1999. Reactive oxygen species activate human peripheral blood dendritic cells. Free Radic. Biol. Med. 26:232-238.
116. Maemura, K., et al. 2005. Reactive oxygen species are essential mediators in antigen presentation by Kupffer cells. Immunol. Cell Biol. 83:336-343.
117. Vosters, O., et al. 2003. Dendritic cells exposed to nacystelyn are refractory to maturation and promote the emergence of alloreactive regulatory T cells. Transplantation. 75:383-389.
118. Verhasselt, V., et al. 1999. N-acetyl-L-cysteine inhibits primary human T cell responses at the dendritic cell level: association with NF-kappaB inhibition. J. Immunol. 162:2569-2574.
119. Matsue, H., et al. 2003. Generation and function of reactive oxygen species in dendritic cells during antigen presentation. J. Immunol. 171:3010-3018.
120. Hildeman, D.A., et al. 1999. Reactive oxygen species regulate activation-induced T cell apoptosis. Immunity. 10:735-744.
121. Grassi, F., and Pacifici, R. 2005. Oxidative stress induced dendritic cell-dependent T cell activation. A novel mechanism by which estrogen deficiency causes bone loss. J. Bone Min. Res. 20:a1144.
122. Elefteriou, F., et al. 2005. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature. 434:514-520.
123. Fox, H.S., Bond, B.L., and Parslow, T.G. 1991. Estrogen regulates the IFN-gamma promoter. J. Immunol. 146:4362-4367.